Abstracts tagged "anti-TNF therapy"

Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
John D. Reveille¹, Atul A. Deodhar², Eric K.H. Chan³, Steven Peterson⁴, Nan Li⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴, Diane D. Harrison⁴ and Chenglong Han⁶, ¹University of Texas McGovern Medical School, Houston, TX, ²Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…
Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Charles Peterfy¹, Joel Kremer², William F C Rigby³, Nora Singer⁴, Christine Birchwood⁵, Darcy Gill⁵, William Reiss⁵, Jinglan Pei⁵ and Margaret Michalska⁵, ¹Spire Sciences, Inc., Boca Raton, FL, ²Albany Medical College, Albany, NY, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Genentech, Inc., South San Francisco, CA
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
Abstract Number: 546 • 2017 ACR/ARHP Annual Meeting
Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis
Ming Zhao¹, Harlan Sayles², James R. O'Dell¹ and Kaleb Michaud^2,3, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) have been widely used in patients who failed conventional DMARDs in the treatment of rheumatoid arthritis (RA). While most…
Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Gareth T. Jones¹, Andrew Keat², Ejaz Pathan³ and Gary J. Macfarlane¹, ¹Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology., Northwick Park Hospital, London, United Kingdom, ³Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…
Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Shalini Mohan¹, Margaret Michalska², Jeffrey Yourish², Jinglan Pei², Sara Gale¹, Christine Birchwood² and Erhan Berber², ¹Genentech, South San Francisco, CA, ²Genentech, Inc., South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…
Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Victor S. Sloan¹, Anna Sheahan¹, Jeffrey Stark² and Robert Y. Suruki¹, ¹UCB Pharma, Raleigh, NC, ²UCB Pharma, Smyrna, GA
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…
Abstract Number: 606 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure in Patients with Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Philip J Mease¹, Iain B. McInnes², Kristian Reich³, Peter Nash⁴, Mats Andersson⁵, Ken Abrams⁶, Luminita Pricop⁶ and Todd Fox⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, United Kingdom, ³Dermatologikum Hamburg, Hamburg, Germany, ⁴University of Queensland, Brisbane, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Pooled safety data from secukinumab psoriasis (PSO) and psoriatic arthritis (PsA) clinical trial programs after ~1 year of exposure have been reported previously.1, 2…
Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², YouFu Li³, Peter Hur⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…
Abstract Number: 630 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial
M. Elaine Husni¹, Arthur Kavanaugh², Eric K. H. Chan³, Nan Li⁴, Steven Peterson⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴ and Diane D. Harrison⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Medicine, University of California, San Diego, La Jolla, CA, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: To evaluate physical and mental health functioning, health state, and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA) treated with…
Abstract Number: 1570 • 2017 ACR/ARHP Annual Meeting
Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Valéria F. Caparbo¹, Carla G.S. Saad¹, Julio C. B. Moraes², Artur J de Brum-Fernandes³ and Rosa M R Pereira⁴, ¹Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Université de Sherbrooke, Rheumatology Division, Canada, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease characterized by new bone growth that leads to syndesmophyte formation and subsequent vertebral ankyloses, although AS…
Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium
Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Jennifer Rammel¹, Patricia Rosillo¹, Tiphanie Vogel² and Marietta de Guzman³, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, ³Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
Abstract Number: 442 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database.
Peter Bhoi¹, Louis Bessette², Mary Bell³, Cathy Tkaczyk⁴, Francois Nantel⁵ and Karina Maslova¹, ¹Janssen Inc., Toronto, ON, Canada, ²Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Subcutaneous (SC) anti-TNF agents such as Golimumab (GLM) Adalimumab (ADA), Etanercept (ETA) and Certolizumab pegol (CZP) Index period was from January 1, 2010 -…
Abstract Number: 699 • 2016 ACR/ARHP Annual Meeting
In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis
Adrian Ciurea¹, Monika Hebeisen², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Raphael Micheroli¹, Lukas Wildi¹, Pascal Zufferey⁶, Michael J. Nissen⁷, Peter M. Villiger⁸, Juerg Bernhard⁹, Désirée van der Heijde¹⁰, RBM Landewé^11,12, Almut Scherer² and Pascale Exer¹³, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁷Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁸Rheumatology, Clinical immunology & Alllergology, University Hospital Bern, Bern, Switzerland, ⁹Rheumatology Center, Buergerspital, Solothurn, Switzerland, ¹⁰Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ¹³Private rheumatology practice, Basel, Switzerland
Background/Purpose: Response to tumor necrosis factor inhibition (TNFi) has been shown to be similar in nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) in patients…
Abstract Number: 2048 • 2016 ACR/ARHP Annual Meeting
Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from a Prospective, Postmarketing, Multicenter Pharmacokinetic Study
Megan E. B. Clowse¹, Frauke Förger², Caroline Hwang³, John Thorp⁴, Radboud J. E. M. Dolhain⁵, Astrid van Tubergen⁶, Laura Shaughnessy⁷, Jeff Simpson⁸, Marie Teil⁹, Nathalie Toublanc¹⁰, Maggie Wang⁸ and Thomas W. Hale¹¹, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Keck Hospital of USC, Los Angeles, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, University Medical Center Rotterdam, Rotterdam, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹Texas Tech University School of Medicine, Amarillo, TX
Background/Purpose: Women with chronic inflammatory diseases, including rheumatic diseases and Crohn’s disease (CD), face uncertainty regarding the safety of the use of biologics during breastfeeding.…
Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…

« Previous Page
1
…
6
7
8
9
10
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].